Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
School of Pharmacy, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown 26506-9520, USA. 911ga@hsc.wvu.edu
Although the anti-oestrogen tamoxifen is recognised as the treatment of choice for both premenopausal and postmenopausal women with advanced hormone-dependent breast cancer, oestrogen deprivation can also be achieved, with apparently less adverse-effects, through selective inhibition of aromatase. Recent clinical trials have demonstrated the efficacy and tolerability of the new generation of aromatase inhibitors as second-line and first-line therapy in postmenopausal women with breast cancers who were eligible for endocrine treatment. Speculating that administration of aromatase inhibitors will not be limited to postmenopausal breast cancer, a pharmacoeconomic perspective is considered based on available data and putative therapeutic application during various phases of the disease.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on